Summary
Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript
Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript
Harrow Q2 Earnings Call Highlights
Harrow NASDAQ: HROW reported second-quarter revenue of $70.7 million, up 11% from a year earlier and about 60% sequentially, as the ophthalmic pharmaceutical company said it entered the second half of 2026 with stronger demand across several products, improved pricing and expanded commercial infrastructure.
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
Harrow (HROW) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.24 per share a year ago.
Harrow Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 75 | $2,512.81 | $2,987.25 | $474.44 | 18.88% |
| PN Peter Nicholson First Bancorp Inc. /ME/ | 1,500 | $63,705 | $61,050 | -$2,655 | -4.17% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,970 | $41,685.2 | $77,657.4 | $35,972.2 | 86.29% |
| NA Nizar Araji National Bank Of Canada /FI/ | 1,499 | $11,856.98 | $60,619.56 | $48,762.58 | 411.26% |
| BG Bart Gancher Intech Investment Management LLC | 8,815 | $318,461.65 | $356,478.6 | $38,016.95 | 11.94% |
Harrow Inc. (HROW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Harrow Inc. ever had a stock split?
Harrow Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mark L. Baum CEO | NASDAQ (NMS) Exchange | 415858109 CUSIP |
| US Country | 373 Employees | - Last Dividend | 8 Feb 2013 Last Split | 28 Sep 2007 IPO Date |
Overview
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of a wide range of ophthalmic pharmaceutical products. Initially founded in 1998 and headquartered in Nashville, Tennessee, the company has a strong focus on addressing the diverse needs within the field of ophthalmology. Its portfolio spans from compounded medications designed for specific patient needs to advanced therapeutic solutions for common and complex eye conditions. Originally known as Harrow Health, Inc., it underwent a name change to Harrow, Inc. in September 2023, reflecting its evolved position and broadened scope in the eyecare pharmaceutical landscape.
Products and Services
- ImprimisRx - A line of ophthalmology-focused compounded medications designed to meet specific patient needs in eye care.
- IHEEZO - Chloroprocaine hydrochloride ophthalmic gel, offering anesthesia for eye procedures.
- Ophthalmic Solutions - Includes products like IOPIDINE, VEVYE, and ZERVIATE, catering to various ophthalmic needs.
- MAXITROL Eye Drops - Provides treatment for bacterial infections, inflammation, and redness in the eyes.
- ILEVRO and NEVANAC - Non-steroidal and anti-inflammatory eye drops for managing pain and inflammation post-cataract surgery.
- VIGAMOX - A fluoroquinolone antibiotic eye drop for treating bacterial conjunctivitis.
- MAXIDEX and FLAREX - Steroid eye drops used for treating various steroid-responsive inflammatory conditions of the eye.
- TRIESENCE - A steroid injection aimed at treating ophthalmic diseases and aiding in visualization during vitrectomy procedures.
- NATACYN - An antifungal drug in sterile form for treating fungal infections of the eye like blepharitis, conjunctivitis, and keratitis.
- TOBRADEX ST - A combined tobramycin and dexamethasone ophthalmic suspension for bacterial infections and inflammation of the eye.
- VERKAZIA - Cyclosporine ophthalmic emulsion used for treating chronic, severe keratitis.
- FRESHKOTE Preservative Free (PF) - A lubricant eye drop designed to relieve dry eye symptoms without the use of preservatives.
